Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
|
31694905 |
2020 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, TBMS1 is a promising compound for the treatment of glioblastoma and an inhibitor of MET.
|
31349699 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our studies reveal a novel mechanism to alter the recycling process of MET in glioblastoma cancer cells by promoting the receptor degradation through a proteasome-sensitive and lysosome-dependent pathway through the ligand-independent activation of MET using anti-MET antibodies.
|
30760737 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the five target genes that were enriched in the glioblastoma pathway, in the WikiPathway database, both HRas proto-oncogene, GTPase and MET proto-oncogene, receptor tyrosine kinase target genes of hsa-miR-139-5p, were found to be significantly associated with patient survival.
|
31423264 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified critical proteins that were altered in MET inhibitor-resistant GBM including mTOR, FGFR1, EGFR, STAT3, and COX-2.
|
30201763 |
2019 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that the level of miR-562 was downregulated in GBM tissues and the expression of c-MET was upregulated in tumors.
|
30613151 |
2019 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, combined treatment with BH3-mimetics and c-MET inhibitors results in significantly smaller tumors than each treatment alone in a PDX model system of glioblastoma.
|
29743557 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
H1/pHGFK1 exerts anti-tumoural and radiosensitive activities mainly through the inhibition and reversal of IR-induced MET and ATM-Chk2 axis activities in glioblastoma.
|
29348487 |
2018 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previously, it was demonstrated that treatment with cabozantinib (MET/VEGFR2/RET inhibitor) prolonged survival of mice carrying orthotopic patient-derived xenografts (PDX) of the MET-addicted glioblastoma model E98, yet did not prevent development of recurrent and cabozantinib-resistant tumors.
|
28751462 |
2017 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GBM tissues frequently overexpressed MET protein at high levels compared with lower-grade gliomas.
|
28668888 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In both cohorts, MET amplification was never detected in GBM devoid of strongly immunopositive cells.
|
26946354 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
|
29238047 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study demonstrates the potential of integrated 11C-MET-PET/MRI for response assessment of GBM and the utility of combined assessment of morphologic and metabolic information with the proposal for assessing relapsed GBM.
|
28258444 |
2017 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This translational correlative component to the MET-PET clinical trials can lead to a better understanding of the existing controversies and can enhance our knowledge for future randomization of GBM patients based on their tumor gene signatures to achieve better prognosis and treatment outcome.
|
29164057 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study we investigated ALK, ROS1, and MET status in nine glioblastoma stem cell lines and tumors from which they arise.
|
28960893 |
2017 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
|
28504721 |
2017 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recurrence of GB after chemo-radiation could be associated with a variation in PlGF and MET expression.
|
27566180 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
|
27748748 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we showed that PKCδ was aberrantly activated in GBM cells by c-MET, a receptor tyrosine kinase hyperactivated in GBM.
|
26700818 |
2016 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
|
26381735 |
2015 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data provide new insights into the potential application of miR-144-3p in GBM therapy by targeting MET and then inhibiting the downstream signaling.
|
26250785 |
2015 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
In contrast to the classical subtype of primary glioblastoma, the cases studied here were characterized by the absence of EGFR amplification, PTEN loss, and 9p homozygous deletion and overexpression of p53, PDGFRα, and c-MET, suggesting that they can be classified as the proneural or mesenchymal subtype of glioblastoma and benefit from intensive therapy that includes temozolomide.
|
24457079 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting Dock7 in GBM may inhibit c-MET-mediated invasion in tumours treated with anti-angiogenic regimens.
|
24518591 |
2014 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tf-NP-miR-1 treatment on GBM spheres significantly inhibited migration of GBM spheres by 30-50% with associated decline of MET and EGFR expression.
|
25374033 |
2014 |
Glioblastoma Multiforme
|
0.400 |
Biomarker
|
disease |
BEFREE |
We show that the RTKs MET, EGFR, and PDGFR regulate microRNA-134 (miR-134) in GBM.
|
24440911 |
2014 |